Ocular Therapeutix (NASDAQ:OCUL) Trading Down 7.6% – What’s Next?

10 Sep 2026, 20:01 by Sarita Garza · The Markets Daily

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report)’s share price dropped 7.6% during mid-day trading on Thursday . The company traded as low as $10.64 and last traded at $10.5940. 1,173,008 shares changed hands during trading, a decline of 71% from the average session volume of 4,006,970 shares. The stock had previously closed at $11.47.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $25.00 price target (up from $21.00) on shares of Ocular Therapeutix in a research report on Thursday, June 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Friday, July 17th. Robert W. Baird raised their price objective on shares of Ocular Therapeutix from $24.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Chardan Capital reaffirmed a “buy” rating and set a $23.00 target price on shares of Ocular Therapeutix in a report on Tuesday, August 4th. Finally, Wall Street Zen upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.75.

Check Out Our Latest Stock Report on OCUL

Ocular Therapeutix Price Performance

The company has a market capitalization of $2.34 billion, a price-to-earnings ratio of -7.49 and a beta of 0.97. The company has a 50-day moving average price of $9.84 and a 200-day moving average price of $9.31. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.03 and a current ratio of 13.10.

Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. The company had revenue of $13.47 million during the quarter, compared to analysts’ expectations of $13.20 million. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%.Ocular Therapeutix’s revenue was down .1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.39) EPS. On average, equities research analysts expect that Ocular Therapeutix, Inc. will post -1.47 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Jeffrey Heier sold 3,296 shares of Ocular Therapeutix stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $10.78, for a total value of $35,530.88. Following the transaction, the insider owned 318,326 shares of the company’s stock, valued at approximately $3,431,554.28. The trade was a 1.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Peter Kaiser sold 3,035 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $10.77, for a total transaction of $32,686.95. Following the completion of the transaction, the insider owned 264,378 shares of the company’s stock, valued at $2,847,351.06. This trade represents a 1.13% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 29,877 shares of company stock worth $321,827. Company insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Ocular Therapeutix

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP bought a new stake in Ocular Therapeutix during the first quarter worth $5,491,000. The Manufacturers Life Insurance Company grew its position in shares of Ocular Therapeutix by 145.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 227,808 shares of the biopharmaceutical company’s stock valued at $1,930,000 after acquiring an additional 135,160 shares during the period. Empire Life Investments Inc. increased its stake in shares of Ocular Therapeutix by 115.0% during the 4th quarter. Empire Life Investments Inc. now owns 540,115 shares of the biopharmaceutical company’s stock worth $6,557,000 after purchasing an additional 288,853 shares during the last quarter. Octagon Capital Advisors LP increased its stake in shares of Ocular Therapeutix by 20.7% during the 1st quarter. Octagon Capital Advisors LP now owns 3,166,600 shares of the biopharmaceutical company’s stock worth $26,821,000 after purchasing an additional 543,000 shares during the last quarter. Finally, BlackRock Inc. bought a new stake in shares of Ocular Therapeutix in the 2nd quarter valued at about $190,278,000. 59.21% of the stock is owned by institutional investors and hedge funds.

Ocular Therapeutix Company Profile

(Get Free Report)

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.